Elicio Therapeutics, Inc. (ELTX)

USD 5.5

(9.56%)

Market Cap (In USD)

87.74 Million

Revenue (In USD)

-

Net Income (In USD)

-35.19 Million

Avg. Volume

41.21 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.96-11.45
PE
-1.29
EPS
-4.25
Beta Value
0.0
ISIN
US28657F1030
CUSIP
28657F103
CIK
1601485
Shares
15953500.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Robert T. Connelly
Employee Count
-
Website
https://elicio.com
Ipo Date
2021-02-05
Details
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.